Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Associated Therapies
- -
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
- Conditions
- HIV InfectionsAIDS
- Interventions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 195
- Registration Number
- NCT00302822
- Locations
- 🇫🇷
Service des Maladies Infectieuses A Hôpital Bichat-Claude Bernard, Paris, France
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
- Conditions
- Leukoencephalopathy, Progressive MultifocalHIV Infections
- First Posted Date
- 2005-07-18
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 30
- Registration Number
- NCT00120367
- Locations
- 🇫🇷
Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre, Le Kremlin Bicetre, France
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 19
- Registration Number
- NCT00051831
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 5
- Registration Number
- NCT00050856
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Adding New Drugs for HIV Infected Patients Failing Current Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 50
- Registration Number
- NCT00031044
- Locations
- 🇺🇸
Miami University, Miami, Florida, United States
🇺🇸Harvard (Massachusetts General Hosp), Boston, Massachusetts, United States
🇵🇷Univ of Puerto Rico, San Juan, Puerto Rico
A Study of T-20 in HIV-Positive Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Trimeris
- Target Recruit Count
- 78
- Registration Number
- NCT00002228
- Locations
- 🇺🇸
Northwestern Univ / Infect Dis Div / Pasavant Pav 828, Chicago, Illinois, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 525
- Registration Number
- NCT00008528
- Locations
- 🇺🇸
Massachusetts Gen Hosp, Boston, Massachusetts, United States
🇺🇸Nicholas Bellos, Dallas, Texas, United States
🇺🇸Univ of Texas Med Branch, Galveston, Texas, United States
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 525
- Registration Number
- NCT00021554
- Locations
- 🇳🇱
Natac Med Centre, Amsterdam, Netherlands
🇳🇱Univ Medical Center Utrecht, CX Utrecht, Netherlands
🇨🇭Univ Hosp Basel / Med Outpatient Dept, Basel, Switzerland
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00002239
- Locations
- 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00022763
- Locations
- 🇺🇸
Children's Hosp Los Angeles, Los Angeles, California, United States
🇺🇸New York Hosp - Cornell / Program for Children with AIDS, New York, New York, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.